Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Th...(ip with leading pharmaceutical companies...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/18/2007
ip with leading pharmaceutical companies including Novartis, AstraZeneca, Bayer Schering and Boehringer Ingelheim.
Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Poster Title: A comparison of the pharmacological profile of AT7519 in solid tumor and hematological cell lines.
--------------------------------------------------------------------
Session Date : Tuesday, October 23, 2007, 12:30 PM
Session Title : Poster Session A
Session Subtitle : Small Molecule Therapeutic Agents: Kinase
Inhibitors
Session Time : 12:30-2:30 PM and 5:30-7:30 PM
Session Location : Exhibit Hall, First Floor, Moscone Convention
Center West
Abstract Number : A247
--------------------------------------------------------------------
Poster Title: AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation.
--------------------------------------------------------------------
Session Date : Wednesday, October 24, 2007, 12:30 PM
Session Title : Poster Session B
Session Subtitle : Small Molecule Therapeutic Agents: Kinase
Inhibitors
Session Time : 12:30-2:30 PM and 5:30-7:30 PM
Session Location : Exhibit Hall, First Floor, Moscone Convention
Center West
Abstract Number : B251
--------------------------------------------------------------------
About Astex
Astex Therapeutics is a biotechnology company that discovers and
develops novel small molecule therapeutics. Using its pioneering
fragment-based drug discovery platform Pyramid(TM), Astex has built a
pipeline of five molecularly-targeted oncology drugs, of which two are
currently being tested in clinical
'/>"/>
| SOURCE Astex Therapeutics Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. What citizens dont ask political candidates
2. Candidates sparring over jobs focuses debate on right issue
3. To find solid security candidates, look beyond tech certificates
4. Presidential candidates stretch necks and facts
5. Innovation featured in NE Wisconsin Roundtable
6. Madison music featured on Internet radio station
7. Wisconsin biotech sector featured in scientific magazine
8. The Information Age of Healthcare - Leaders featured on local new economy show
9. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
10. Olympics of biotechnology has international flavor
11. Traffic data firm navigates international business
Post Your Comments:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9[0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)[0] VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291[0] Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India[0] Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities
Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference
Video shows buckyballs form by 'shrink wrapping'
Other Biology Technology:Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016 2XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference 2Video shows buckyballs form by 'shrink wrapping' 2Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care ConferenceVideo shows buckyballs form by 'shrink wrapping'
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 1Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 3MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 1MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 2MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 1Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 2Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 4Many African-Americans have a gene that prolongs life after heart failure
Research identifies first method for testing, assessing drug treatments for Chagas' disease
UTMB inventions win University of Texas System commercialization awards
Other Biology News:Many African-Americans have a gene that prolongs life after heart failure 2Many African-Americans have a gene that prolongs life after heart failure 3Many African-Americans have a gene that prolongs life after heart failure 4Research identifies first method for testing, assessing drug treatments for Chagas' disease 2Research identifies first method for testing, assessing drug treatments for Chagas' disease 3UTMB inventions win University of Texas System commercialization awards 2X-GAL (5-Bromo-4-Chloro-3-Indolyl-Beta-D-Galactopyranoside), = 99.0% from AMRESCO, Inc.
Custom Peptide Synthesis from Raybiotech, Inc.
DTNB from Cayman Chemical
Keyhole Limpet Hemocyanin NP-KLH (Keyhole Limpet Hemocyanin), Unconjugated from Biosearch Technologies
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |